Taken together, these results indicate the comparative effectiveness of oxaliplatin+palbociclib combination therapy against drug-naïve CCA and CDK4/6 inhibitor-resistant CCA cells in the in vivo settings. This evidence concerns the gene CDK4 and cholangiocarcinoma.